Home  |  Contact

Cellosaurus HT1376rGEMCI20 (CVCL_RR16)

[Text version]
Cell line name HT1376rGEMCI20
Accession CVCL_RR16
Resource Identification Initiative To cite this cell line use: HT1376rGEMCI20 (RRID:CVCL_RR16)
Comments Part of: Resistant Cancer Cell Line (RCCL) collection.
Population: Caucasian.
Doubling time: 41.8 hours (PubMed=26055179).
Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (from parent cell line).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1292 (HT-1376)
Sex of cell Female
Age at sampling 58Y
Category Cancer cell line
Web pages https://www.wass-michaelislab.org/rccl.php
Publications

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_RR16
Encyclopedic resources Wikidata; Q54896572
Entry history
Entry creation05-Mar-2018
Last entry update05-Oct-2023
Version number11